Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Irreversible Electroporation in Advanced Pancreatic Adenocarcinoma
NCT03080974Phase 2Recruiting
- Sponsor
- University of Louisville
- Start
- Aug 2017
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in pancreatic adenocarcinoma (PDAC), sponsored by University of Louisville. Started Aug 2017; status: recruiting.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03080974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03080974.